Bayer’s Three-Pronged Offensive: A Landmark Ruling, an Antidumping Petition, and a US Spin-Off Fuel a Historic Rally

Bayer stock surges 54% in 30 days after Supreme Court blocks Roundup lawsuits, trade war move, and spin-off speculation.

Bayer’s stock has more than doubled over the past twelve months, but the real fireworks have come in the last 30 days. The shares surged nearly 54% in that span alone, closing Friday at €53.04 and just shy of a new 52-week high of €53.86 set a week earlier. The rally has been driven not by a single catalyst, but by a coordinated push on three fronts: a decisive legal victory, a new trade war offensive, and a structural reorganization of its US glyphosate business.

The most recent move came from the courtroom. In late June, the US Supreme Court ruled 7–2 against John Durnell, a cancer patient who had argued that Roundup’s packaging failed to warn of health risks. The decision effectively blocks thousands of similar lawsuits built on the same premise of inadequate warning labels. For Bayer, which faces roughly 65,000 Roundup-related claims in the US, the ruling removes a significant layer of legal overhang. The company denies any causal link between the herbicide and cancer.

Even before the Supreme Court decision, Bayer had already moved to cap its litigation exposure. In February it struck a $7.25 billion class-action settlement covering many of those claims. The final approval hearing, originally set for an earlier date, has now been pushed to August 19 by a Missouri court. Bayer’s Monsanto subsidiary said the delay does not materially affect the process. The opt-out deadline has already passed, though the exact acceptance rate remains unclear. The settlement will only take effect once all appeals are exhausted.

Alongside the legal progress, Bayer has gone on the offensive in trade policy. On June 30, 2026, through its Monsanto unit and the newly created Ruveon LLC, it filed a petition with the US Department of Commerce and the International Trade Commission seeking anti-dumping and countervailing duties on glyphosate imports from China. Bayer argues it is the last remaining US producer of the herbicide and that Chinese rivals have been selling at artificially low, market-distorting prices. It remains uncertain whether the agencies will even open an investigation, let alone how much any tariffs might boost Bayer’s revenue.

The creation of Ruveon itself has added a layer of strategic intrigue. The new entity, based in St. Louis, is officially a wholly owned subsidiary of Bayer and part of a five-year restructuring plan for the Crop Science division. It will manage pricing, production, and logistics autonomously for the US market. But analysts see more than just operational efficiency. Stefan Wulf at ODDO BHF argues the separate structure is a clear preparatory step for a future sale or initial public offering. Bayer denies any such plans, but the market has seized on the speculation as another reason to buy.

The sheer speed of the advance has pushed the stock deep into overbought territory. The relative strength index stands at 85.1, well above the 70 threshold that typically signals a short-term pullback. The shares now trade 36.5% above their 50-day moving average of €38.86 and nearly 43% above their 200-day moving average. Annualized volatility has climbed past 63%, suggesting trading days will remain choppy.

Investors now have two key dates on the calendar. On August 4, Bayer is scheduled to report second-quarter earnings, with particular attention on whether the company is making progress in reducing its €32.5 billion debt load. Eight days later, on August 19, the Missouri court will hold the settlement approval hearing. Until then, the market must weigh the unmistakable fundamental tailwinds against a chart that is flashing red. The question is whether the rally can consolidate – or whether an overbought market will demand a pause first.